Marc ENGELHARDT,Anne SCHMITT-HOFFMANN,Patrice LARGER
申请号：
US16611524
公开号：
US20200237730A1
申请日:
2018.05.15
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention provides a novel dosage principle for compounds of formula I and pharmaceutically acceptable derivatives thereof as defined in the claims, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient over a period of at least about 8 hours, wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45 mg/m2 of the dihydrochloride salt of the compound of formula I-B as defined in the claims.
